source
- Sanofi's Infilbray receives first U.S. approval for treating neurological symptoms of Gaucher diseaseSanofi announced that the U.S. Food and Drug Administration has granted approval for Infilbray, a therapy aimed at the neurological manifestations of Gaucher disease, a rare genetic disorder. The…
- Study finds malaria antibody L9LS reduces vaccine response in infantsResearchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…